Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 14/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6639312 | 0.99 | BACE1 (0.51) | BACE1PGRCYP1A2MAPTCYP2C19 | |
| SCHEMBL29609794 | 0.85 | PGR (0.58) | PGRCYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL25399999 | 0.85 | PGR (0.58) | PGRCYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL4715658 | 0.83 | PGR (0.59) | PGRCYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL6637484 | 0.83 | PGR (0.54) | BACE1PGRKMT2AHTR2APDE4A | |
| SCHEMBL17596705 | 0.82 | BACE1 (0.49) | BACE1PGRHTR2APDE4APDE4B | |
| SCHEMBL1950989 | 0.82 | CYP1A2 (0.53) | BACE1PGRCYP1A2MAPTCYP2C19 | |
| Hydrochloric Acid SCHEMBL6639499 | 0.82 | PGR (0.53) | BACE1PGRKMT2AHTR2APDE4A | |
| SCHEMBL2268702 | 0.81 | CYP1A2 (0.63) | PGRCYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL7504206 | 0.80 | BACE1 (0.47) | BACE1PGRHTR2APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1426375-A2 | Analgesic spiroindole derivatives | AstraZeneca AB (SE) | 2004-06-09 | — | — | EP | claimed |
| US-20040087800-A1 | Spirooxindole derivatives are analgesics for the treatment of chronic pain. | ASTRAZENECA AB | 2004-05-06 | — | — | US | claimed |
| EP-1202994-B1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2004-04-14 | — | — | EP | claimed |
| EP-1202994-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2002-05-08 | — | — | EP | claimed |
| WO-2001005790-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2001-01-25 | — | — | WO | claimed |
| US-6774132-B1 | Spirooxindole derivatives that act as analgesics | ASTRAZENECA AB (SE) | 2004-08-10 | — | — | US | disclosed |
| EP-1426375-A2 | Analgesic spiroindole derivatives | AstraZeneca AB (SE) | 2004-06-09 | — | — | EP | disclosed |
| US-20040087800-A1 | Spirooxindole derivatives are analgesics for the treatment of chronic pain. | ASTRAZENECA AB | 2004-05-06 | — | — | US | disclosed |
| EP-1202994-B1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| EP-1202994-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001005790-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087800-A1 | Spirooxindole derivatives are analgesics for the treatment of chronic pain. | OPRK1, OPRD1, OPRL1 | BACE1 4822/4885PGR 1652/4885CYP1A2 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.